Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Arcutis Gets FDA Review for Zoryve 0.05% Label Expansion (ARQT)

Summary by Seeking Alpha
Arcutis Biotherapeutics (ARQT) stock gains as the FDA agrees to review the company's bid to expand the label of its eczema therapy Zoryve 0.05% cream. Read more here.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT)

Arcutis Biotherapeutics (ARQT) stock gains as the FDA agrees to review the company's bid to expand the label of its eczema therapy Zoryve 0.05% cream. Read more here.

·Ra'anana, Israel
Read Full Article
Arcutis BiotherapeuticsArcutis Biotherapeutics

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Open the article to view the coverage from Arcutis Biotherapeutics

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Arcutis Biotherapeutics broke the news on Wednesday, July 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal